Tandem Diabetes Care Announces FDA Clearance of Remote Software Update Tool for Insulin Pumps
"This clearance, combined with the flexibility provided by our pumps'
touchscreen interfaces, uniquely positions Tandem as the only insulin
pump company with the ability to provide its customers access to new and
enhanced features, separate from the typical multi-year warranty
hardware replacement cycle," said
The first use of the Tandem Device Updater will be for deployment of the
latest t:slim® Insulin Pump software to in-warranty t:slim Pumps
The Company intends to roll out the Tandem Device Updater first to early t:slim Pump users throughout the summer in a series of test groups, followed by an expanded launch later this year.
For more information on the Tandem Device Updater, including how to sign up to be a part of the early test groups, please visit www.tandemdiabetes.com/updater.
t:slim, t:flex and
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding: the potential for the Tandem Device Updater to be used to deliver in-warranty product innovation without requiring the replacement of hardware and make it easier for the Company to bring new products to customers faster than the industry has been able to in the past; the Company's ability to offer future software improvements and enhancements to Tandem pumps using the Tandem Device Updater; the scope and timing of the Company's anticipated rollout of the Tandem Device Updater; and the Company's efforts towards developing an artificial pancreas. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, successful commercialization of the Company's products, including the Tandem Device Updater, may be negatively impacted by lack of market acceptance by physicians, payors and people with diabetes; the potential that newer products that compete with the Company's products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the Company's products, including the Tandem Device Updater, obsolete or less desirable; the potential that the Tandem Device Updater may fail to perform according to its specifications or may not provide people with diabetes with anticipated benefits; and the potential that some or all of the future software improvements and enhancements to Tandem pumps may not be approved by the
News Provided by Acquire Media